The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 07, 2017

Filed:

Jul. 01, 2016
Applicants:

The United States of America, As Represented BY the Secretary of Agriculture, Washington, DC (US);

The University of Connecticut, Storrs, CT (US);

Inventors:

Manuel V. Borca, Westbrook, CT (US);

Douglas P. Gladue, Guilford, CT (US);

Lauren G. Holinka-Patterson, Deep River, CT (US);

Guillermo R. Risatti, Westbrook, CT (US);

Vivian K. O'Donnell, Old Saybrook, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12Q 1/70 (2006.01); G01N 33/569 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C12N 7/00 (2013.01); C12Q 1/701 (2013.01); G01N 33/56983 (2013.01); A61K 2039/5256 (2013.01); C12N 2710/12021 (2013.01); C12N 2710/12034 (2013.01); C12N 2710/12071 (2013.01); G01N 2333/01 (2013.01);
Abstract

African swine fever virus (ASFV) is the etiological agent of a contagious, often lethal viral disease of domestic pigs. The control of African Swine Fever (ASF) has been hampered by the unavailability of vaccines. Experimental vaccines have been derived from naturally occurring, cell culture-adapted, or genetically modified live attenuated ASFVs; however, these vaccines are only successful when protecting against homologous viruses. We have constructed a recombinant Δ9GL/ΔUK virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate by deleting the specific virulence-associated 9GL (B119L) and the UK (DP96R) genes. In vivo, ASFV-G Δ9GL/ΔUK administered intramuscularly to swine even at relatively high doses (10HAD) does not induce disease. Importantly, animals infected with 10or 10HADare solidly protected against the presentation of clinical disease when challenged at 28 days post infection with the virulent parental strain Georgia 2007.


Find Patent Forward Citations

Loading…